CPT Stock Overview
A regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
CollPlant Biotechnologies Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.50 |
| 52 Week High | US$6.00 |
| 52 Week Low | US$3.00 |
| Beta | 0.48 |
| 11 Month Change | 12.18% |
| 3 Month Change | -15.87% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | -19.35% |
| Change since IPO | -14.15% |
Recent News & Updates
Recent updates
Shareholder Returns
| CPT | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -1.1% | -0.7% | -0.02% |
| 1Y | n/a | -17.2% | 8.2% |
Return vs Industry: Insufficient data to determine how CPT performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how CPT performed against the German Market.
Price Volatility
| CPT volatility | |
|---|---|
| CPT Average Weekly Movement | 8.6% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: CPT's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: CPT's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 75 | Yehiel Tal | www.collplant.com |
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company’s products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures.
CollPlant Biotechnologies Ltd. Fundamentals Summary
| CPT fundamental statistics | |
|---|---|
| Market cap | €45.81m |
| Earnings (TTM) | -€16.78m |
| Revenue (TTM) | €661.65k |
68.8x
P/S Ratio-2.7x
P/E RatioIs CPT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CPT income statement (TTM) | |
|---|---|
| Revenue | US$689.00k |
| Cost of Revenue | US$2.13m |
| Gross Profit | -US$1.44m |
| Other Expenses | US$16.03m |
| Earnings | -US$17.47m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 27, 2024
| Earnings per share (EPS) | -1.53 |
| Gross Margin | -209.43% |
| Net Profit Margin | -2,535.70% |
| Debt/Equity Ratio | 0% |
How did CPT perform over the long term?
See historical performance and comparison